27348517|t|Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel - Chelator Complex on Biodistribution and Tumor Uptake
27348517|a|Bradykinin B1 receptor (B1R), which is upregulated in a variety of malignancies, is an attractive cancer imaging biomarker. In this study we optimized the selection of radiolabel - chelator complex to improve tumor uptake and tumor -to-background contrast of radiolabeled analogues of B9958 (Lys-Lys-Arg-Pro-Hyp-Gly-Cpg-Ser-d-Tic-Cpg), a potent B1R antagonist. Peptide sequences were assembled on solid phase. Cold standards were prepared by incubating DOTA -/ NODA - conjugated peptides with GaCl3, and by incubating AlOH - NODA -conjugated peptide with NaF. Binding affinities were measured via in vitro competition binding assays. (68)Ga and (18)F labeling experiments were performed in acidic buffer and purified by HPLC. Imaging / biodistribution studies were performed in mice bearing both B1R-positive (B1R+) HEK293T :: hB1R and B1R-negative (B1R-) HEK293T tumors. Z02176 (Ga-DOTA-Pip-B9958; Pip: 4-amino-(1-carboxymethyl)piperidine), Z02137 (Ga-NODA-Mpaa-Pip-B9958; Mpaa: 4-methylphenylacetic acid), and Z04139 (AlF-NODA-Mpaa-Pip-B9958) bound h B1R with high affinity (Ki = 1.4-2.5 nM). (68)Ga -/ (18)F - labeled peptides were obtained on average in ≥32% decay-corrected radiochemical yield with >99% radiochemical purity and 100-261 GBq/μmol specific activity. Biodistribution / imaging studies at 1 h postinjection showed that all tracers cleared rapidly from background tissues (except kidneys) and were excreted predominantly via the renal pathway. Only kidneys, bladders, and B1R+ tumors were clearly visualized in PET images. Uptake in B1R+ tumor was higher by using (68)Ga - Z02176 (28.9 ± 6.21 %ID/g) and (18)F - Z04139 (22.6 ± 3.41 %ID/g) than (68)Ga - Z02137 (14.0 ± 4.86 %ID/g). The B1R+ tumor-to-blood and B1R+ tumor-to-muscle contrast ratios were also higher for (68)Ga - Z02176 (56.1 ± 17.3 and 167 ± 57.6) and (18)F - Z04139 (58.0 ± 20.9 and 173 ± 42.9) than (68)Ga - Z02137 (34.3 ± 15.2 and 103 ± 30.2). With improved target-to-background contrast (68)Ga - Z02176 and (18)F - Z04139 are promising for imaging B1R expression in cancers with PET.
27348517	13	30	B9958 Derivatives	T103	UMLS:C0002776
27348517	35	42	Imaging	T058	UMLS:C0011923
27348517	43	65	Bradykinin B1 Receptor	T103	UMLS:C0384601
27348517	66	76	Expression	T038	UMLS:C1171362
27348517	82	110	Positron Emission Tomography	T058	UMLS:C0032743
27348517	139	147	Chelator	T103	UMLS:C0007974
27348517	148	155	Complex	T103	UMLS:C1704241
27348517	179	184	Tumor	T038	UMLS:C0027651
27348517	185	191	Uptake	T038	UMLS:C3888108
27348517	192	214	Bradykinin B1 receptor	T103	UMLS:C0384601
27348517	216	219	B1R	T103	UMLS:C0384601
27348517	231	242	upregulated	T038	UMLS:C0041904
27348517	259	271	malignancies	T038	UMLS:C0006826
27348517	305	314	biomarker	T201	UMLS:C0005516
27348517	324	329	study	T062	UMLS:C2603343
27348517	373	381	chelator	T103	UMLS:C0007974
27348517	382	389	complex	T103	UMLS:C1704241
27348517	401	406	tumor	T038	UMLS:C0027651
27348517	407	413	uptake	T038	UMLS:C3888108
27348517	418	423	tumor	T038	UMLS:C0027651
27348517	477	482	B9958	T103	UMLS:C1721886
27348517	537	551	B1R antagonist	T103	UMLS:C3850093
27348517	553	570	Peptide sequences	T103	UMLS:C0030956
27348517	645	649	DOTA	T103	UMLS:C0088359
27348517	653	657	NODA	T103	UMLS:C0029224
27348517	660	670	conjugated	T082	UMLS:C0522529
27348517	671	679	peptides	T103	UMLS:C0030956
27348517	685	690	GaCl3	T103	UMLS:C0021521
27348517	710	714	AlOH	T103	UMLS:C0002371
27348517	717	721	NODA	T103	UMLS:C0029224
27348517	734	741	peptide	T103	UMLS:C0030956
27348517	747	750	NaF	T103	UMLS:C0037508
27348517	752	759	Binding	T038	UMLS:C1167622
27348517	789	824	in vitro competition binding assays	T058	UMLS:C0201712
27348517	826	832	(68)Ga	T103	UMLS:C0303226
27348517	837	842	(18)F	T103	UMLS:C0302995
27348517	843	863	labeling experiments	T062	UMLS:C0022261
27348517	882	895	acidic buffer	T103	UMLS:C0006353
27348517	912	916	HPLC	T058	UMLS:C0008562
27348517	918	925	Imaging	T058	UMLS:C0011923
27348517	944	951	studies	T062	UMLS:C2603343
27348517	970	974	mice	T204	UMLS:C0025929
27348517	988	1000	B1R-positive	T103	UMLS:C0384601
27348517	1002	1006	B1R+	T103	UMLS:C0384601
27348517	1008	1015	HEK293T	T017	UMLS:C0007634
27348517	1019	1023	hB1R	T017	UMLS:C0007634
27348517	1028	1040	B1R-negative	T033	UMLS:C1513916
27348517	1042	1046	B1R-	T033	UMLS:C1513916
27348517	1048	1055	HEK293T	T017	UMLS:C0007634
27348517	1056	1062	tumors	T038	UMLS:C0027651
27348517	1064	1070	Z02176	T103	UMLS:C0030956
27348517	1072	1089	Ga-DOTA-Pip-B9958	T103	UMLS:C0030956
27348517	1091	1094	Pip	T103	UMLS:C0031960
27348517	1096	1132	4-amino-(1-carboxymethyl)piperidine)	T103	UMLS:C0031960
27348517	1134	1140	Z02137	T103	UMLS:C0030956
27348517	1142	1164	Ga-NODA-Mpaa-Pip-B9958	T103	UMLS:C0030956
27348517	1166	1170	Mpaa	T103	UMLS:C0070620
27348517	1172	1197	4-methylphenylacetic acid	T103	UMLS:C0070620
27348517	1204	1210	Z04139	T103	UMLS:C0030956
27348517	1212	1235	AlF-NODA-Mpaa-Pip-B9958	T103	UMLS:C0030956
27348517	1245	1248	B1R	T103	UMLS:C0384601
27348517	1287	1293	(68)Ga	T103	UMLS:C0303226
27348517	1297	1302	(18)F	T103	UMLS:C0302995
27348517	1313	1321	peptides	T103	UMLS:C0030956
27348517	1371	1384	radiochemical	T103	UMLS:C0599914
27348517	1401	1414	radiochemical	T103	UMLS:C0599914
27348517	1480	1487	imaging	T058	UMLS:C0011923
27348517	1488	1495	studies	T062	UMLS:C2603343
27348517	1533	1540	tracers	T103	UMLS:C1522485
27348517	1573	1580	tissues	T017	UMLS:C0040300
27348517	1589	1596	kidneys	T017	UMLS:C0022646
27348517	1607	1615	excreted	T038	UMLS:C0221102
27348517	1638	1651	renal pathway	T038	UMLS:C0035070
27348517	1658	1665	kidneys	T017	UMLS:C0022646
27348517	1667	1675	bladders	T017	UMLS:C0005682
27348517	1681	1685	B1R+	T103	UMLS:C0384601
27348517	1686	1692	tumors	T038	UMLS:C0027651
27348517	1720	1723	PET	T058	UMLS:C0032743
27348517	1724	1730	images	T170	UMLS:C1704922
27348517	1732	1738	Uptake	T038	UMLS:C3888108
27348517	1742	1746	B1R+	T103	UMLS:C0384601
27348517	1747	1752	tumor	T038	UMLS:C0027651
27348517	1773	1779	(68)Ga	T103	UMLS:C0303226
27348517	1782	1788	Z02176	T103	UMLS:C0030956
27348517	1813	1818	(18)F	T103	UMLS:C0303226
27348517	1821	1827	Z04139	T103	UMLS:C0030956
27348517	1853	1859	(68)Ga	T103	UMLS:C0303226
27348517	1862	1868	Z02137	T103	UMLS:C0030956
27348517	1976	1982	(68)Ga	T103	UMLS:C0303226
27348517	1985	1991	Z02176	T103	UMLS:C0030956
27348517	2025	2030	(18)F	T103	UMLS:C0303226
27348517	2033	2039	Z04139	T103	UMLS:C0030956
27348517	2074	2080	(68)Ga	T103	UMLS:C0303226
27348517	2083	2089	Z02137	T103	UMLS:C0030956
27348517	2164	2170	(68)Ga	T103	UMLS:C0303226
27348517	2173	2179	Z02176	T103	UMLS:C0030956
27348517	2184	2189	(18)F	T103	UMLS:C0303226
27348517	2192	2198	Z04139	T103	UMLS:C0030956
27348517	2217	2224	imaging	T058	UMLS:C0011923
27348517	2225	2228	B1R	T103	UMLS:C0384601
27348517	2229	2239	expression	T038	UMLS:C1171362
27348517	2243	2250	cancers	T038	UMLS:C0006826
27348517	2256	2259	PET	T058	UMLS:C0032743